<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Journal of Medical Microbiology and Infectious Diseases</title>
<title_fa>Journal of Medical Microbiology and Infectious Diseases</title_fa>
<short_title>JoMMID</short_title>
<subject>Medical Sciences</subject>
<web_url>http://jommid.pasteur.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2345-5349</journal_id_issn>
<journal_id_issn_online>2345-5330</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.61882/JoMMID</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1399</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2021</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<volume>9</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Protection and Immune Responses Elicited by rSAG1-PLGA Nanoparticles in C57BL/6 Against Toxoplasma gondii</title>
	<subject_fa>Immune responses, deficiencies and vaccine candidates </subject_fa>
	<subject>Immune responses, deficiencies and vaccine candidates </subject>
	<content_type_fa>Original article</content_type_fa>
	<content_type>Original article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;strong&gt;Introduction: &lt;/strong&gt;This study aimed to evaluate rSAG1-PLGA efficacy as a particulate vaccine in conferring protection against &lt;em&gt;Toxoplasma gondii&lt;/em&gt; infection in C57BL/6 mice. In light of our previous studies, we studied mice genotype role in eliciting immune responses by rSAG1-PLGA nanoparticles in this study. &lt;strong&gt;Methods: &lt;/strong&gt;Poly (DL-lactide-co-glycolide) (PLGA) nanoparticles loaded by rSAG1 as a subunit vaccine were prepared, and C57BL/6 mice were subcutaneously immunized twice at a 3-week interval by rSAG1-PLGA, soluble rSAG1, blank PLGA, and one group kept unvaccinated. The characteristics of PLGA nanoparticles, the amounts of produced IFN-&amp;gamma;, IL-10, specific anti-&lt;em&gt;Toxoplasma&lt;/em&gt;IgGs, and the conferred protection against infection by &lt;em&gt;T. gondii&lt;/em&gt; RH tachyzoite were assessed. &lt;strong&gt;Results: &lt;/strong&gt;rSAG1-PLGA nanoparticles shared a z-average of about 450nm with negative Zeta potential. Compared with the negative control group, the mice vaccinated with rSAG1-PLGA nanoparticles produced significantly higher amounts of IFN-&amp;gamma;, specific anti-&lt;em&gt;T. gondii &lt;/em&gt;IgG antibodies and higher titer of IgG2a, which resulted in longer survival times.&lt;strong&gt; Conclusion:&lt;/strong&gt; The efficiency of rSAG1-PLGA nanoparticles in inducing humoral and cellular responses and consequently partial protection against acute toxoplasmosis in C57BL/6 was confirmed.</abstract>
	<keyword_fa></keyword_fa>
	<keyword>: rSAG1-PLGA, Toxoplasma gondii, vaccine, C57BL/6, nanoparticles</keyword>
	<start_page>38</start_page>
	<end_page>45</end_page>
	<web_url>http://jommid.pasteur.ac.ir/browse.php?a_code=A-10-322-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Mojgan</first_name>
	<middle_name></middle_name>
	<last_name>Allahyari</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>mojalah@yahoo.com</email>
	<code></code>
	<orcid>0000-0002-7370-9315</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Recombinant Protein Production Department, Production and Research Complex, Pasteur Institute of Iran, Karaj, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Samira</first_name>
	<middle_name></middle_name>
	<last_name>amiri</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>samiraamiri.86@gmail.com</email>
	<code></code>
	<orcid>0000-0001-9753-5738</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Molecular Parasitology Laboratory, Department of  Parasitology, Pasteur Institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Alireza</first_name>
	<middle_name></middle_name>
	<last_name>Vatanara</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>vatanara@sina.tums.ac.ir</email>
	<code></code>
	<orcid>0000-0002-4293-8633</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Majid</first_name>
	<middle_name></middle_name>
	<last_name>Golkar</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>majid.golkar@gmail.com</email>
	<code></code>
	<orcid>0000-0002-0052-2410</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Molecular Parasitology Laboratory, Department of  Parasitology, Pasteur Institute of Iran, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
